|
|
Vaccine Detail
|
AuNP-Conjugated Fluoroproline-Modified S-Linked Tn-MUC1 Glycopeptide Vaccine |
| Vaccine Information |
- Vaccine Name: AuNP-Conjugated Fluoroproline-Modified S-Linked Tn-MUC1 Glycopeptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Ghirardello et al., 2025)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A synthetic cancer vaccine consisting of a chemically modified MUC1 glycopeptide conjugated to gold nanoparticles (AuNPs). The vaccine features an engineered MUC1-derived peptide with an artificial Tn antigen bearing an S-glycosidic linkage (oxygen-to-sulfur substitution) and a fluoroproline residue inserted in the peptide backbone. The glycopeptide is covalently attached to AuNPs via thiol-maleimide coupling. Vaccination in mice elicits high IgG1 antibody titers (Th2-type response) that cross-react with tumor-associated MUC1 (TA-MUC1) expressed on human breast cancer cells (MCF7, T47D), promote antibody-dependent cell-mediated cytotoxicity (ADCC; 40% target cell lysis at 3:1 effector:target ratio), and specifically recognize cancer tissue in immunohistochemical assays of patient biopsies (n=5) with no binding to healthy tissue. Reducing the surface density of MUC1 antigen on AuNPs through co-loading with an ovalbumin-derived peptide maintains equivalent immunogenicity, demonstrating flexibility for future multicomponent vaccine design. MUC1 antigen, a membrane-bound glycoprotein expressed on epithelial cells, is overexpressed with aberrant glycosylation characterized by short, truncated glycans in most epithelial cancers including breast, ovarian, lung, colorectal, prostate, pancreatic, and stomach cancers (Ghirardello et al., 2025).
|
| Host Response |
|
|
| References |
Ghirardello et al., 2025: Ghirardello M, Guerreiro A, Bretón C, Compañón I, Zabalza J, Mangini V, Peregrina JM, Bernardes GJL, Corzana F. Balancing Antigen Loading on Gold Nanoparticles: Implications for Future Cancer Vaccine Strategies. Chemistry (Weinheim an der Bergstrasse, Germany). 2025; 31(38); e202501286. [PubMed: 40448390].
|
|
